State Street Corp Has $1.53 Million Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI)

State Street Corp boosted its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 17.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 601,542 shares of the biopharmaceutical company’s stock after purchasing an additional 87,504 shares during the quarter. State Street Corp owned about 1.23% of Puma Biotechnology worth $1,534,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Puma Biotechnology by 63.6% during the second quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 120,104 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in Puma Biotechnology during the 2nd quarter valued at about $335,000. Rhumbline Advisers increased its holdings in Puma Biotechnology by 2,309.9% during the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 48,184 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Puma Biotechnology in the second quarter worth approximately $54,000. Finally, Rice Hall James & Associates LLC lifted its holdings in shares of Puma Biotechnology by 3.3% in the second quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 4,686 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Price Performance

Puma Biotechnology stock opened at $3.05 on Thursday. The stock has a market cap of $149.72 million, a P/E ratio of 6.35 and a beta of 1.08. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average price is $2.98 and its two-hundred day moving average price is $2.98. Puma Biotechnology, Inc. has a 52 week low of $2.22 and a 52 week high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million for the quarter, compared to analysts’ expectations of $71.32 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. On average, equities analysts predict that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analyst Ratings Changes

PBYI has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.